{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:57:08Z","timestamp":1791928628255,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Genelux Corporation, Westlake Village, CA","award":["N\/A."],"award-info":[{"award-number":["N\/A."]}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1136\/ijgc-2023-004812","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T05:35:12Z","timestamp":1693805712000},"page":"1458-1463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant\/refractory ovarian cancer"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct05281471","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3121-4605","authenticated-orcid":false,"given":"Robert W.","family":"Holloway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto A.","family":"Mendivil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5180-0409","authenticated-orcid":false,"given":"Sarfraz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed N.","family":"Al-Niaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Barter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setsuko K.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Crafton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad","family":"Ghamande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Graybill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan Dr","family":"Indermaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena S.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Landrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Lucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McHale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6985-0159","authenticated-orcid":false,"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen Nadine","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3992-8610","authenticated-orcid":false,"given":"Debra","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Scalici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Arin","family":"Silasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnansu","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward W.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004812_bb0010","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2164-10-301","article-title":"Systemic treatment of xenografts with vaccinia virus GLV-1H68 reveals the immunologic facet of oncolytic therapy","volume":"10","author":"Worschech","year":"2009","journal-title":"BMC Genomics"},{"key":"10.1136\/ijgc-2023-004812_bb0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1535-7163.MCT-08-0533","article-title":"Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1H68","volume":"8","author":"Yu","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1136\/ijgc-2023-004812_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-11-451","article-title":"Permissivity of the NCI-60 cancer cell lines to oncolytic vaccinia virus GLV-1H68","volume":"11","author":"Ascierto","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2023-004812_bb0025","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-11-68","article-title":"Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection","volume":"11","author":"Weibel","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2023-004812_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056317","article-title":"Imaging of intratumoral inflammation during oncolytic virotherapy of tumors by 19F-magnetic resonance imaging (MRI)","volume":"8","author":"Weibel","year":"2013","journal-title":"PLoS One"},{"key":"10.1136\/ijgc-2023-004812_bb0035","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","article-title":"Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis","volume":"24","author":"Lauer","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-004812_bb0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2021.10.069","article-title":"A phase 1B study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer","volume":"163","author":"Manyam","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004812_bb0045","first-page":"A9","author":"Holloway","year":"2020","journal-title":"12\u2005Oncolytic vaccinia (Olvi-Vec) primed immunochemotherapy in platinum-resistant\/refractory ovarian cancer"},{"key":"10.1136\/ijgc-2023-004812_bb0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamaoncol.2023.1007","article-title":"Clinical activity of olvimulogene nanivacirepvec-primed immunochemotherapy in heavily pretreated patients with platinum-resistant or platinum-refractory ovarian cancer: the nonrandomized phase 2 VIRO-15 clinical trial","volume":"9","author":"Holloway","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2023-004812_bb0055","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.mt.6300221","article-title":"Chemotherapy enhances CD8(+) T-cell-mediated antitumor immunity induced by vaccination with vaccinia virus","volume":"15","author":"Song","year":"2007","journal-title":"Mol Ther"},{"key":"10.1136\/ijgc-2023-004812_bb0060","doi-asserted-by":"crossref","first-page":"12915","DOI":"10.1073\/pnas.0900660106","article-title":"Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy","volume":"106","author":"Frentzen","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ijgc-2023-004812_bb0065","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40259-019-00367-0","article-title":"Oncolytic viruses: priming time for cancer immunotherapy","volume":"33","author":"Russell","year":"2019","journal-title":"BioDrugs"},{"key":"10.1136\/ijgc-2023-004812_bb0070","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-016-1096-1","article-title":"Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells","volume":"14","author":"Kilinc","year":"2016","journal-title":"J Transl Med"},{"key":"10.1136\/ijgc-2023-004812_bb0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3290","article-title":"Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer","volume":"3","author":"Ovarian Tumor Tissue Analysis (OTTA) Consortium","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2023-004812_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00070","article-title":"Control of the immune response by pro-angiogenic factors","volume":"4","author":"Voron","year":"2014","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2023-004812_bb0085","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004812_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00016","article-title":"Role of BRCA mutations in the modulation of response to platinum therapy","volume":"8","author":"Mylavarapu","year":"2018","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2023-004812_bb0095","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/2326-6066.CIR-14-0101","article-title":"Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer","volume":"2","author":"Mariya","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1136\/ijgc-2023-004812_bb0100","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004812_bb0105","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.21.00334","article-title":"Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA)","volume":"39","author":"Hamanishi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004812_bb0110","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004812_bb0115","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2023-004812_bb0120","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2023-004812_bb0125","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004812_bb0130","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.19.00194","article-title":"Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives","volume":"37","author":"Pujade-Lauraine","year":"2019","journal-title":"JCO"},{"key":"10.1136\/ijgc-2023-004812_bb0135","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\" ovarian cancer: what is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004812_bb0140","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/gyno.2002.6855","article-title":"Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients","volume":"88","author":"Nagourney","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004812_bb0145","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1179\/joc.2007.19.5.577","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience","volume":"19","author":"Germano","year":"2007","journal-title":"J Chemother"},{"key":"10.1136\/ijgc-2023-004812_bb0150","author":"National Comprehensive Cancer Network","year":"2023","journal-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines): ovarian cancer continue including Fallopian tube cancer and primary peritoneal cancer, version 1"},{"key":"10.1136\/ijgc-2023-004812_bb0155","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-19-1638","article-title":"A randomized phase II trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer","volume":"26","author":"Oza","year":"2020","journal-title":"Clin Cancer Res"}],"updated-by":[{"DOI":"10.1136\/ijgc-2023-004812corr1","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000}}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2401702X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2401702X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004812","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:41:51Z","timestamp":1753224111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2401702X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1048891X2401702X"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004812","relation":{"erratum":[{"id-type":"doi","id":"10.1136\/ijgc-2023-004812corr1","asserted-by":"object"}]},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant\/refractory ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}